Business
IXICO announces updates to client contracts
IXICO announces updates to client contracts.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 7335X IXICO plc 23 December 2019 \n\n23 December 2019\nIXICO plc\n(\"IXICO\" or the \"Company\")\n \n IXICO announces updates to client contracts\n \n £2.4 million expansion of study programmes with two large pharma client contracts\n \nIXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces:\n \n· c£1.8 million extension to a Phase III study in Huntington's Disease (HD), previously announced in September 2018; and\n· c£0.6 million extension to a study programme in Progressive Supranuclear Palsy (PSP), previously announced in October 2019.\n \n \nGiulio Cerroni, Chief Executive Officer of IXICO, commented: \n \n\"HD and PSP are devastating neurological conditions, currently with no cure, and we are pleased to build momentum in our mission to support our clients in delivering data analytics in these challenging areas of rare, neurodegenerative disease. Our services will enable them to measure the impact of the trialled drugs with greater confidence and potentially unlock new insights into disease progression.\n \n \"Following the recent announcement of our strong trading results for FY19, the expansion of these work programmes for two large pharma clients is further evidence of the value that we deliver through our proprietary AI data analytics and our ability to scale our operations to meet increasing size and complexity of clinical trials as they progress through clinical development.\"\n \n \n \nFor further information please contact: \n \n\n\n\nIXICO plc\n\n\n+44 (0) 20 3763 7498\n\n\n\n\nGiulio Cerroni, Chief Executive Officer\nGrant Nash, Chief Financial Officer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCenkos Securities PLC (Nominated adviser and sole broker)\n\n\n+44 (0) 20 7397 8900\n\n\n\n\nGiles Balleny / Max Gould (Corporate Finance)\n\n\n\n\n\n\n\nMichael F Johnson / Russell Kerr (Sales)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOptimum Strategic Communications\n\n\n +44 (0) 203 950 9144\n\n\n\n\nMary Clark, Supriya Mathur, Manel Mateus\n\n\n\n\n\n\n\[email protected]\n\n\n\n\n\n\n \nAbout IXICO\nIXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights ...